MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Charles River Laboratories International Inc

Затворен

СекторЗдравеопазване

149.32 2.42

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

142.29

Максимум

149.91

Ключови измерители

By Trading Economics

Приходи

-284M

-214M

Продажби

-7.2M

1B

P/E

Средно за сектора

752.6

63.778

EPS

2.66

Марж на печалбата

-21.32

Служители

18,700

EBITDA

-296M

-86M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+19.66% upside

Дивиденти

By Dow Jones

Следващи печалби

8.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-476M

8B

Предишно отваряне

146.9

Предишно затваряне

149.32

Настроения в новините

By Acuity

8%

92%

7 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Charles River Laboratories International Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.08.2024 г., 10:30 ч. UTC

Топ новини

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Charles River Laboratories International Inc Прогноза

Ценова цел

By TipRanks

19.66% нагоре

12-месечна прогноза

Среден 174.69 USD  19.66%

Висок 188 USD

Нисък 155 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Charles River Laboratories International Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

14 ratings

0

Купи

14

Задържане

0

Продай

Техническа оценка

By Trading Central

145.66 / 159.08Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

7 / 386 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.